Cargando…
PTBP1 modulates osteosarcoma chemoresistance to cisplatin by regulating the expression of the copper transporter SLC31A1
Chemoresistance is the main obstacle of treatment in patients with osteosarcoma. RNA‐binding protein PTBP1 has been identified as an oncogene in various cancers. However, the role of PTBP1 in osteosarcoma, especially in chemoresistant osteosarcoma, and the underlying mechanism remain unclear. In thi...
Autores principales: | Cheng, Cheng, Ding, Qiuyue, Zhang, Zhicai, Wang, Shangyu, Zhong, Binlong, Huang, Xin, Shao, Zengwu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205786/ https://www.ncbi.nlm.nih.gov/pubmed/32207235 http://dx.doi.org/10.1111/jcmm.15183 |
Ejemplares similares
-
Dynasore suppresses cell proliferation, migration, and invasion and enhances the antitumor capacity of cisplatin via STAT3 pathway in osteosarcoma
por: Zhong, Binlong, et al.
Publicado: (2019) -
Bruceine D inhibits tumor growth and stem cell‐like traits of osteosarcoma through inhibition of STAT3 signaling pathway
por: Wang, Shangyu, et al.
Publicado: (2019) -
Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis
por: Huang, Xin, et al.
Publicado: (2018) -
Transcription factor ELK1 accelerates aerobic glycolysis to enhance osteosarcoma chemoresistance through miR-134/PTBP1 signaling cascade
por: Zhang, Qiang, et al.
Publicado: (2021) -
Dysregulated Expression of Circular RNAs Serve as Prognostic and Clinicopathological Markers in Cancer
por: Huang, Xin, et al.
Publicado: (2019)